Concurrent HIV/AIDS diagnosis increases the risk of short-term HIV-related death among persons newly diagnosed with AIDS, 2002-2005

AIDS Patient Care and STDs

Volumn 22, Issue 1, 2008, Pages 17-28

  Hanna, David B ^a   Pfeiffer, Melissa R ^a   Torian, Lucia V ^a   Sackoff, Judith E ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; BIRTHPLACE; CAUSE OF DEATH; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; DISEASE NOTIFICATION; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MORTALITY; NEW YORK CITY; POPULATION SURVEILLANCE; REGISTRIES; TIME FACTORS;

EID: 38149086957     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0042     Document Type: Article

References (56)

1. Chiasson MA, Berenson L, Li W, et al. Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr 1999;21:59-64.
2. HIV Epidemiology Program-NYC Dept. of Health and Mental Hygiene. New York City HIV/AIDS Annual Surveillance Statistics. December 4, 2006. www.nyc.gov/html/doh/html/ah/hivtables.shtml. (Last accessed March 5, 2007).
3. New York City Bureau of Vital Statistics. Summary of Vital Statistics 2005: The City of New York. www.nyc.gov/html/doh/downloads/pdf/vs/2005sum.pdf. (Last accessed March 5, 2007).
4. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51:1-52.
5. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-135.
6. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998;12:29-33.
7. Osmond DH, Chin DP, Glassroth J, et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Pulmonary Complications of HIV Study Group. Clin Infect Dis 1999;29:536-543.
8. Seage GR, 3rd, Losina E, Goldie SJ, Paltiel AD, Kimmel AD, Freedberg KA. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts to chronic mortality. J Acquir Immune Defic Syndr 2002;30:421-428.
9. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002;16:1945-1951.
10. Centers for Disease Control and Prevention. Late versus early testing of HIV - 16 Sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep 2003;52:581-586.
11. McDonald AM, Li Y, Dore GJ, Ree H, Kaldor JM. Late HIV presentation among AIDS cases in Australia, 1992-2001. Aust N Z J Public Health 2003;27:608-613.
12. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med 2004;5:93-98.
13. Manavi K, McMillan A, Ogilvie M, Scott G. Heterosexual men and women with HIV test positive at a later stage of infection than homo- or bisexual men. Int J STD AIDS 2004;15:811-814.
14. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: Uptake of and responses to antiretroviral therapy. AIDS 2004;18:2145-2151.
15. Brannstrom J, Akerlund B, Arneborn M, Blaxhult A, Giesecke J. Patients unaware of their HIV infection until AIDS diagnoss in Sweden 1996-2002 - A remaining problem in the highly active antiretroviral therapy era. Int J STD AIDS 2005;16:702-706.
16. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004. Atlanta: US Dept of Health and Human Serv, Centers for Disease Control and Prevention, 2005.
17. Longo B, Pezzotti P, Boros S, Urciuoli R, Rezza G. Increasing proportion of late testers among AIDS cases in Italy, 1996-2002. AIDS Care 2005;17:834-841.
18. Gilbart VL, Dougan S, Sinka K, Evans BG. Late diagnosis of HIV infection among individuals with low, unrecognised or unacknowledged risks in England, Wales and Northern Ireland. AIDS Care 2006;18:133-139.
19. Bonnet F, Lewden C, May T, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 2005;37:482-487.
20. Chadborn TR, Baster K, Delpech VC, et al. No time to wait: How many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005;19:513-520.
21. Santos J, Palacios R, Ruiz J, Gonzalez M, Marquez M. Study of patients diagnosed with advanced HIV in the HAART era - OMEGA Cohort. Int J STD AIDS 2005;16:252-255.
22. Sabin CA, Smith CJ, Youle M, et al. Deaths in the era of HAART: Contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006;20:67-71.
23. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006;20:2371-2379.
24. HIV Epidemiology Program-NYC Dept. of Health and Mental Hygiene. HIV Epidemiology Program 1st Quarter Report. New York City: New York City Department of Health and Mental Hygiene, January 2006.
25. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
26. Greenberg AE, Hindin R, Nicholas AG, Bryan EL, Thomas PA. The completeness of AIDS case reporting in New York City. JAMA 1993;269:2995-3001.
27. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organization, 1993.
28. National Center for Health Statistics. What is the NDI? www.cdc.gov/nchs/r&d/ndi/what_is_ndi.htm. (Last accessed March 5, 2007).
29. Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: The Public Health Disparities Geocoding Project. Am J Epidemiol 2002;156:471-482.
30. Lee LM, McKenna MT, Janssen RS. Classification of transmission risk in the national HIV/AIDS surveillance system. Public Health Rep 2003;118:400-407.
31. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: Wiley, 1987.
32. Schafer JL, Olsen MK. Multiple imputation for multivariate missing-data problems: a data analyst's perspective. Multivariate Behav Res 1998;33:545-571.
33. Molenberghs G, Williams PL, Lipsitz SR. Prediction of survival and opportunistic infections in HIV-infected patients: A comparison of imputation methods of incomplete CD4 counts. Stat Med 2002;21:1387-1408.
34. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145:397-406.
35. Selik RM, Anderson RN, McKenna MT, Rosenberg HM. Increase in deaths caused by HIV infection due to changes in rules for selecting underlying cause of death. J Acquir Immune Defic Syndr 2003;32:62-69.
36. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute, 1995.
37. Greenland S. Applications of Stratified Analysis Methods. In: Rothman KJ, Greenland S, eds. Modern Epidemiology, 2nd ed. Philadelphia: Lippincott; 1998: 281-300.
38. HIV Epidemiology Program-NYC Dept. of Health and Mental Hygiene. HIV Epidemiology Program 4th Quarter Report. New York City: New York City Department of Health and Mental Hygiene, October 2005.
39. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-129.
40. Lee N, Hogg RS, Yip B, et al. Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy. J Infect Dis 2003;188:137-141.
41. Blum S, Singh TP, Gibbons J, et al. Trends in survival among persons with acquired immunodeficiency syndrome in New York City. The experience of the first decade of the epidemic. Am J Epidemiol 1994;139:351-361.
42. Wong T, Chiasson MA, Reggy A, Simonds RJ, Heffess J, Loo V. Antiretroviral therapy and declining AIDS mortality in New York City. J Urban Health 2000;77:492-500.
43. Nash D, Katyal M, Shah S. Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001. J Urban Health 2005;82:584-600.
44. Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health 2005;95:1439-1444.
45. Uphold CR, Mkanta WN. Review: Use of health care services among persons living with HIV infection: State of the science and future directions. AIDS Patient Care STDS 2005;19:473-485.
46. Torian L, Wiewel E, Hanna D, Sackoff J. Risk factors for failure to initiate primary care after diagnosis of HIV, New York City: Impact of transmission risk and site of initial diagnosis on successful transition to care. XVI International AIDS Conference. Toronto: 2006.
47. Perlman DC, Des Jarlais DC, Salomon N, Masson CL. Preventing opportunistic infections in HIV-infected injection drug users. JAMA 1997;278:1743-1744.
48. Menendez BS, Vermund SH, Drucker E, Blum S. Race/ethnic-specific AIDS risk in New York City, 1981-87. Am J Public Health 1989;79:1679-1680.
49. Selik RM, Castro KG, Pappaioanou M, Buehler JW. Birthplace and the risk of AIDS among Hispanics in the United States. Am J Public Health 1989;79:836-839.
50. Estrada AL. Drug use and HIV risks among African-American, Mexican-American, and Puerto Rican drug injectors. J Psychoactive Drugs 1998;30:247-253.
51. Kim M, Van Wye G, Kerker B, Thorpe L, Frieden T. The Health of Immigrants in New York City. June 2006; http://www.nyc.gov/html/doh/downloads/pdf/episrv/ episrv-immigrant-report.pdf. (Last accessed August 3, 2006).
52. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1-17.
53. Delpierre C, Cuzin L, Lauwers-Cances V, Marchou B, Lang T. High-risk groups for late diagnosis of HIV infection: A need for rethinking testing policy in the general population. AIDS Patient Care STDs 2006;20:838-847.
54. Passin WF, Kim AS, Hutchinson AB, Crepaz N, Herbst JH, Lyles CM. A systematic review of HIV partner counseling and referral services: Client and provider attitudes, preferences, practices, and experiences. Sex Transm Dis 2006;33:320-328.
55. Frieden TR, Das-Douglas M, Kellerman SE, Henning KJ. Applying public health principles to the HIV epidemic. N Engl J Med 2005;353:2397-2402.
56. Bernicker EH, Atmar RL, Schaffner DL, Greenberg SB. Unanticipated diagnoses found at autopsy in an urban public teaching hospital. Am J Med Sci 1996;311:215-220.